The increase in price target by Piper Sandler suggests a positive reassessment of Myriad Genetics' value, potentially leading to increased investor interest and a short-term positive impact on the stock price. The Neutral rating indicates that the analyst sees the company as adequately valued at current levels, but the raised target suggests an expectation of some growth or improvement.